ArticleEmerging infectious diseases2025
Case-Control Study of Factors Associated with Hemolytic Uremic Syndrome among Shiga Toxin-Producing Escherichia coli Patients, Ireland, 2017-2020.
Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Shiga toxin-centered pathophysiology defines the therapeutic limits of enterohemorrhagic Escherichia coli infection.Archives of microbiology · 2026Review
- Emerging Nanomaterials-Based Biosensors for the Clinical and Pathological Detection of E. Coli O157:H7.Current microbiology · 2026Review
- Biophysical Features of Outer Membrane Vesicles (OMVs) from PathogenicAntibiotics (Basel, Switzerland) · 2026Article
- A case report of postpartum hemolytic uremic syndrome.American journal of translational research · 2026Article
- Comparative genomics of Shiga toxin-producingFrontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shiga toxin-producing Escherichia coli (STEC) infection can cause potentially fatal hemolytic uremic syndrome (HUS). To determine epidemiologic and bacterial genomic factors associated with HUS, we conducted a retrospective case-control study with 108 HUS cases and 416 unmatched controls (non-HUS) selected among STEC notifications in Ireland during 2017-2020. We combined routinely collected epidemiologic data on STEC notifications with genomewide association study findings and used logistic regression to estimate adjusted odds ratios. Our findings reaffirmed known risk factors, such as young age (0-9 years) and presence of specific stx genes or gene combinations (stx2a; stx1a + stx2a; stx1a + stx2c), and additionally suggest that having outbreak-associated infection, residence within the East region of Ireland, and the combined presence of both ygiW and group_5720 or both pfkA and fieF genes are potentially associated with developing HUS. Our findings could improve early identification of high-risk STEC infections and help guide enhanced surveillance and public health management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.